# Parabilis Medicines **Source:** https://geo.sig.ai/brands/parabilis-medicines **Vertical:** Healthcare & Life Sciences **Subcategory:** AI Peptide Therapeutics **Tier:** Challenger **Website:** parabilis.com **Last Updated:** 2026-04-14 ## Summary Clinical-stage biotech; raised $305M Series F (Jan 2026) for AI-optimized peptides targeting intracellular cancer proteins previously considered undruggable; oncology-first pipeline ## Company Overview Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.\n\nThe company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.\n\nParabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms. ## Frequently Asked Questions ### What does Parabilis Medicines do? Parabilis uses AI to design peptide drugs that can penetrate cancer cells and block the activity of oncogenic proteins that are otherwise undruggable by conventional small molecules or biologics. The company's platform engineers short peptide chains with the cell permeability and stability needed to reach intracellular targets. ### Why focus on peptides for undruggable cancer proteins? Many cancer-driving proteins lack the pockets or clefts needed for small molecule binding and are too complex for antibodies, which cannot enter cells. Peptides occupy a middle ground: they can be designed to mimic binding interfaces, engineered for cell entry, and optimized by AI for both potency and drug-like properties — making them viable candidates where other modalities fail. ### How is Parabilis funded? Parabilis closed a $305M Series F in January 2026, one of the largest single biotech rounds of that year. The capital is earmarked for advancing lead cancer programs through clinical trials and broadening the AI-designed peptide pipeline across additional undruggable oncology targets. ### What is Parabilis Medicines? Parabilis Medicines is a biotech company developing novel small molecule therapeutics — applying computational chemistry and AI-guided medicinal chemistry to design drug candidates with improved selectivity and reduced side effect profiles. ### What therapeutic areas does Parabilis focus on? Parabilis focuses on oncology and other diseases where improved target selectivity is critical — developing drugs that hit the intended target more precisely than existing therapies, reducing off-target effects that cause side effects. ### How does Parabilis use AI in its chemistry? Parabilis applies generative AI and machine learning to molecule design — generating and evaluating candidate structures computationally before synthesis, focusing lab resources on the most promising compounds rather than broad exploratory screening. ### What stage is Parabilis Medicines at? Parabilis is a clinical-stage or preclinical biotech company working to advance its drug candidates through IND-enabling studies and early clinical trials — the high-risk, high-reward stage where AI-guided design can provide meaningful competitive advantages. ### What makes Parabilis Medicines' approach distinctive? Parabilis combines AI-driven design with deep medicinal chemistry expertise — using computational tools to generate candidates while relying on experienced chemists to guide the AI with domain knowledge about synthesizability and drug-like properties. ### What is Parabilis Medicines? Parabilis Medicines is a clinical-stage biotechnology company developing targeted therapies for cancer treatment, with a focus on novel mechanisms of action in oncology that address resistance pathways in tumors that have failed standard-of-care treatments. ### What therapeutic area does Parabilis focus on? Parabilis focuses on oncology, specifically developing small molecule or biologic therapies targeting molecular pathways that drive cancer cell growth and resistance to existing treatments, with an emphasis on patient populations with limited treatment options. ### What stage is Parabilis Medicines at? Parabilis is a pre-clinical to early clinical stage company, advancing lead compounds through IND-enabling studies and early Phase 1 trials to establish safety, pharmacokinetics, and early efficacy signals in cancer patients. ### Who backs Parabilis Medicines? Parabilis Medicines is backed by life sciences venture capital investors focused on oncology drug development. The company operates in a competitive biotech space where novel mechanism discovery and strong translational science are key to differentiation. ### What is Parabilis Medicines' development approach? Parabilis uses a biomarker-driven development strategy, identifying patient subpopulations most likely to respond to its therapies based on tumor molecular profiling, enabling more efficient clinical trials and a higher probability of demonstrating meaningful efficacy in targeted patient groups. ### What therapeutic area does Parabilis Medicines focus on? Parabilis Medicines focuses on oncology, specifically developing next-generation antibody-drug conjugates (ADCs) — precision cancer therapies that combine a cancer-targeting antibody with a cytotoxic drug payload. ADCs have emerged as one of the most active drug development areas in oncology following blockbuster approvals like Enhertu. ### What makes Parabilis' ADC approach differentiated? Parabilis uses proprietary linker-payload technology designed to improve the therapeutic window of ADCs — releasing the cytotoxic payload more precisely in the tumor microenvironment while reducing off-target toxicity. This technology aims to overcome limitations of first-generation ADCs that caused significant side effects due to premature drug release. ### Who are Parabilis Medicines' investors and partners? Parabilis Medicines has attracted investment from leading oncology-focused venture capital firms. The ADC space has seen significant deal activity with major pharmaceutical companies, creating potential partnership and licensing opportunities for clinical-stage ADC programs from companies like Parabilis. ### What is the ADC market opportunity that Parabilis is targeting? The antibody-drug conjugate market is projected to exceed $20B globally by the late 2020s, with multiple new ADC approvals expected across breast cancer, lung cancer, and hematologic malignancies. Parabilis is positioned to capture value either through independent development or through licensing partnerships with Big Pharma companies building ADC portfolios. ### What stage of development are Parabilis Medicines' programs in? Parabilis is focused on preclinical and IND-enabling studies for its ADC pipeline programs, advancing candidates toward first-in-human clinical trials. The company's development timeline follows typical oncology Phase 1 progression, with lead programs targeting validated cancer antigens where clinical proof-of-concept data already exists. ### What therapeutic area does Parabilis Medicines focus on? Parabilis Medicines is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for inflammatory and immune-mediated diseases. The company applies mechanistic insights into disease biology to identify drug targets with high therapeutic potential in conditions with significant unmet medical need. ### What is Parabilis Medicines' drug discovery approach? Parabilis uses a biology-first approach to drug discovery, starting from deep mechanistic understanding of disease pathways to identify novel molecular targets and design compounds with optimized selectivity and pharmacological properties. The company focuses on creating differentiated therapies rather than incremental improvements on existing drug classes. ### What is Parabilis Medicines' development stage and funding? Parabilis is a clinical-stage company funded by venture capital to advance its pipeline through early clinical trials. As a pre-revenue development company, its milestones center on clinical data readouts, IND submissions, and partnership deals that validate the scientific and commercial potential of its programs. ### Who are Parabilis Medicines' leadership and scientific advisors? Parabilis assembled a leadership team and scientific advisory board with expertise in immunology, drug development, and biopharmaceutical operations. The company draws on advisors with track records in developing approved immunology therapeutics and deep expertise in the regulatory pathways for autoimmune and inflammatory disease indications. ### How does Parabilis Medicines differentiate from large biopharma companies working in inflammation? Parabilis competes in discovery and early development against large biopharma companies including AbbVie (Humira/Skyrizi), Pfizer, and Johnson & Johnson that have established inflammation franchises. As a startup, Parabilis can take on higher-risk novel target bets that large pharma companies are less likely to prioritize, with the goal of becoming an acquisition target as clinical data emerges. ## Tags healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*